News

SkylineDx Announces Prognostic Tool to be Used as Part of Major New Myeloma Clinical Trial

ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today announced that...

SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)

Clinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS) Rotterdam, the Netherlands and Laguna Hills, CA, July 25, 2017 – SkylineDx today announced the...

SkylineDx Presented New Algorithm Demonstrating Ability to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival

Presentation at BioSB 2017 Demonstrated Value of GESTURE™ for Identifying Patient Subgroups Likely to Benefit from Anti-Cancer Treatment Rotterdam, the Netherlands and Laguna Hills, CA, April 10, 2017 – SkylineDx announced that they...

SkylineDx Announces Multiple Studies Being Presented at the 58th Annual ASH Meeting Reinforcing Utility of MMprofiler™ Gene-Based Prognostic Signature to Impact Treatment of Patients with Multiple Myeloma

New Studies Demonstrate Value of Gene Expression Risk Profiling to Identify Ultra-High-Risk Multiple Myeloma Patients Rotterdam, the Netherlands and Laguna Hills, CA, November 29, 2016 – SkylineDx today announced the presentation of new...

SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan

The Japanese Patent Office Has Notified SkylineDx of the Decision to Grant a Patent for the SKY92 Gene Signature Rotterdam, the Netherlands, Laguna Hills, CA, Tokyo, Japan, October 11, 2016 – SkylineDx is...

SkylineDx and Consortium of Leading European Partners awarded multi-million Euro Horizon2020 grant from European Commission

Project Focuses on Development of Gene Expression Profiling Tool to Predict Treatment Outcomes for Patients with Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 4, 2016 – SkylineDx today announced it...

SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)

Studies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016 – SkylineDx today announced the...

SkylineDx Supports Myeloma Awareness Month to Raise Awareness of a Serious and Difficult to Treat Disease

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., March 8, 2016 — SkylineDx today announces its support for Myeloma Awareness Month, an effort conducted throughout the month of March by the International Myeloma Foundation (IMF)...

SkylineDx to Present New Data Demonstrating Prognostic Value of MMprofiler™ in Multiple Myeloma at American Society of Hematology Annual Meeting

Studies Support Use of MMprofiler™ for Stratifying High and Low-Risk in Newly Diagnosed Elderly and Relapsed Patients MassGen Poster Highlights Use of MMprofiler™ in Phase II Modified RVD (Revlimid/Velcade/Dexamethasone) Trial Rotterdam, the...

SkylineDx Receives CE-IVD Mark for MMprofiler™ — Its Innovative Gene Signature-Based Test for Multiple Myeloma

CE-IVD Approval Marks SkylineDx’s European Commercialization of its MMprofiler technology Rotterdam, the Netherlands and Laguna Hills, CA, November 25, 2015 – SkylineDx, today announced they have received CE-IVD registration from the European Competent...

SKY92-ISS Superior to current markers in risk classification for myeloma survival

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at the...

SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO

Key additions to the management team as SkylineDx accelerates its development of gene signature-based diagnostics and prepares for the launch of its first product Rotterdam, The Netherlands, 19 August 2015 – SkylineDx, a...

More Accurate Prediction on Prognosis in Multiple Myeloma (bone marrow cancer)

Test of Dutch-based SkylineDx gives patients better insight in their chances and enables clinicians to adjust their treatment Rotterdam, 2 July 2015 – SkylineDx, an innovative biotechnology company specialising in the development and...

SkylineDx Presents an Abstract on Risk Identification for Multiple Myeloma Patients at the 20th Congress of the EHA

Boston (U.S.) – Rotterdam (NL), June 8, 2015. On the 13th of June SkylineDx will present an abstract detailing the comparison of SKY92 GEP, IFISH AND ISS for risk identification in Multiple...